In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants

AIDS. 2016 Aug 24;30(13):2135-7. doi: 10.1097/QAD.0000000000001156.

Authors

Lisanne Denneman¹, Sophie Cohen, Mieke H Godfried, Elisabeth van Leeuwen, Jeannine F B Nellen, Taco W Kuijpers, Dasja Pajkrt, Atie van de Plas, Colette Smit, Anouschka M Weijsenfeld, Henriette J Scherpbier, Madeleine J Bunders

Affiliation

¹ aDepartment of Paediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Centre (AMC), University of Amsterdam (UvA), Amsterdam bDepartment of Paediatrics, Amphia Hospital, Breda cDepartment of Internal Medicine dDepartment of Gynaecology and Obstetrics, AMC, UvA eHIV Monitoring Foundation fDepartment of Experimental Immunology, AMC, UvA, Amsterdam, The Netherlands. *Henriette J. Scherpbier and Madeleine J. Bunders contributed equally to the writing of this article.

PMID: 27465280
DOI: 10.1097/QAD.0000000000001156

No abstract available

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / administration & dosage
Anti-HIV Agents / adverse effects*
Birth Weight / drug effects
Child Development / drug effects
Female
Fetal Development / drug effects
Fetal Growth Retardation / chemically induced
Follow-Up Studies
Growth Disorders / chemically induced*
HIV Infections / drug therapy
HIV Infections / transmission*
Humans
Infant
Infectious Disease Transmission, Vertical / prevention & control*
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
Prenatal Exposure Delayed Effects / chemically induced*
Retrospective Studies
Tenofovir / administration & dosage
Tenofovir / adverse effects*

Substances

Anti-HIV Agents
Tenofovir